-
Je něco špatně v tomto záznamu ?
Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors
M. Steinbügl, K. Nemes, P. Johann, T. Kröncke, S. Tüchert, MJG. da Costa, M. Ebinger, U. Schüller, A. Sehested, P. Hauser, H. Reinhard, D. Sumerauer, S. Hettmer, M. Jakob, M. Hasselblatt, R. Siebert, O. Witt, J. Gerss, K. Kerl, MC. Frühwald
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
34347371
DOI
10.1002/pbc.29267
Knihovny.cz E-zdroje
- MeSH
- azacytidin terapeutické užití MeSH
- decitabin terapeutické užití MeSH
- dítě MeSH
- dospělí MeSH
- lidé MeSH
- lokální recidiva nádoru farmakoterapie genetika MeSH
- prognóza MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- retrospektivní studie MeSH
- rhabdoidní nádor * farmakoterapie genetika MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Refined therapy has helped to improve survival rates in rhabdoid tumors (RT). Prognosis for patients with chemoresistant, recurrent, or progressive RT remains dismal. Although decitabine, an epigenetically active agent, has mainly been evaluated in the management of hematologic malignancies in adults, safety in children has also been demonstrated repeatedly. MATERIALS AND METHODS: A retrospective series of patients who received decitabine upon relapse or progression following therapy according to the EU-RHAB regimen is presented. Due to the retrospective nature of analyses, response was defined as measurable regression of at least one lesion on imaging. 850k methylation profiling was done whenever tumor tissue was available. RESULTS: A total of 22 patients with RT of any anatomical localization were included. Most patients (19/22) presented with metastases. All received low-dose decitabine with or preceding conventional chemotherapy. Patients received a median of two (1-6) courses of decitabine; 27.3% (6/22) demonstrated a radiological response. Molecular analyses revealed increased methylation levels in tumors from responders. No excessive toxicity was observed. Clinical benefits for responders included eligibility for early phase trials or local therapy. Responders showed prolonged time to progression and overall survival. Due to small sample size, statistical correction for survivorship bias demonstrated no significant effect on survival for responders. CONCLUSIONS: Patients with RT demonstrate promising signs of antitumor activity after multiagent relapse therapy including decitabine. Analyses of methylation data suggest a specific effect on an epigenetic level. We propose to consider decitabine and other epigenetic drugs as candidates for further clinical investigations in RT.
Department of Diagnostic and Interventional Radiology University Medical Center Augsburg Germany
Department of Paediatrics and Adolescent Medicine Rigshospitalet Copenhagen Denmark
Department of Pediatric Hematology and Oncology University Hospital Motol Prague Czech Republic
Department of Pediatric Oncology 2nd Department of Pediatrics Semmelweis University Budapest Hungary
Department of Pediatrics Asklepios Kinderklinik Sankt Augustin Sankt Augustin Germany
Hopp Children's Cancer Center Heidelberg and Heidelberg University Hospital Heidelberg Germany
Institute of Biostatistics and Clinical Research University of Münster Muenster Germany
Institute of Human Genetics University of Ulm and Ulm University Hospital Ulm Germany
Institute of Neuropathology University Hospital Münster Münster Germany
Institute of Neuropathology University Medical Center Hamburg Eppendorf Hamburg Germany
Research Institute Children's Cancer Center Hamburg Hamburg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019626
- 003
- CZ-PrNML
- 005
- 20220804135834.0
- 007
- ta
- 008
- 220720s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/pbc.29267 $2 doi
- 035 __
- $a (PubMed)34347371
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Steinbügl, Mona $u University Medical Center Augsburg, Paediatric and Adolescent Medicine, Swabian Children's Cancer Center, Augsburg, Germany
- 245 10
- $a Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors / $c M. Steinbügl, K. Nemes, P. Johann, T. Kröncke, S. Tüchert, MJG. da Costa, M. Ebinger, U. Schüller, A. Sehested, P. Hauser, H. Reinhard, D. Sumerauer, S. Hettmer, M. Jakob, M. Hasselblatt, R. Siebert, O. Witt, J. Gerss, K. Kerl, MC. Frühwald
- 520 9_
- $a BACKGROUND: Refined therapy has helped to improve survival rates in rhabdoid tumors (RT). Prognosis for patients with chemoresistant, recurrent, or progressive RT remains dismal. Although decitabine, an epigenetically active agent, has mainly been evaluated in the management of hematologic malignancies in adults, safety in children has also been demonstrated repeatedly. MATERIALS AND METHODS: A retrospective series of patients who received decitabine upon relapse or progression following therapy according to the EU-RHAB regimen is presented. Due to the retrospective nature of analyses, response was defined as measurable regression of at least one lesion on imaging. 850k methylation profiling was done whenever tumor tissue was available. RESULTS: A total of 22 patients with RT of any anatomical localization were included. Most patients (19/22) presented with metastases. All received low-dose decitabine with or preceding conventional chemotherapy. Patients received a median of two (1-6) courses of decitabine; 27.3% (6/22) demonstrated a radiological response. Molecular analyses revealed increased methylation levels in tumors from responders. No excessive toxicity was observed. Clinical benefits for responders included eligibility for early phase trials or local therapy. Responders showed prolonged time to progression and overall survival. Due to small sample size, statistical correction for survivorship bias demonstrated no significant effect on survival for responders. CONCLUSIONS: Patients with RT demonstrate promising signs of antitumor activity after multiagent relapse therapy including decitabine. Analyses of methylation data suggest a specific effect on an epigenetic level. We propose to consider decitabine and other epigenetic drugs as candidates for further clinical investigations in RT.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a azacytidin $x terapeutické užití $7 D001374
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a decitabin $x terapeutické užití $7 D000077209
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lokální recidiva nádoru $x farmakoterapie $x genetika $7 D009364
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a rhabdoidní nádor $x farmakoterapie $x genetika $7 D018335
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Nemes, Karolina $u University Medical Center Augsburg, Paediatric and Adolescent Medicine, Swabian Children's Cancer Center, Augsburg, Germany
- 700 1_
- $a Johann, Pascal $u University Medical Center Augsburg, Paediatric and Adolescent Medicine, Swabian Children's Cancer Center, Augsburg, Germany $u Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany
- 700 1_
- $a Kröncke, Thomas $u Department of Diagnostic and Interventional Radiology, University Medical Center, Augsburg, Germany
- 700 1_
- $a Tüchert, Stefanie $u Department of Diagnostic and Interventional Radiology, University Medical Center, Augsburg, Germany
- 700 1_
- $a da Costa, Maria Joao Gil $u Pediatric Hematology and Oncology Division, University Hospital S. João Alameda Hernani Monteiro, Porto, Portugal
- 700 1_
- $a Ebinger, Martin $u Department of General Pediatrics, Hematology and Oncology, Children's University Hospital, Tübingen, Germany $1 https://orcid.org/0000000242298058
- 700 1_
- $a Schüller, Ulrich $u Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany $u Research Institute Children's Cancer Center Hamburg, Hamburg, Germany $u Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Sehested, Astrid $u Department of Paediatrics and Adolescent Medicine Rigshospitalet, Copenhagen, Denmark
- 700 1_
- $a Hauser, Peter $u Department of Pediatric Oncology, 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000283078975
- 700 1_
- $a Reinhard, Harald $u Department of Pediatrics, Asklepios Kinderklinik Sankt Augustin, Sankt Augustin, Germany
- 700 1_
- $a Sumerauer, David $u Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Hettmer, Simone $u Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany $1 https://orcid.org/0000000317094448
- 700 1_
- $a Jakob, Marcus $u Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Hospital of Regensburg, Regensburg, Germany
- 700 1_
- $a Hasselblatt, Martin $u Institute of Neuropathology, University Hospital Münster, Münster, Germany
- 700 1_
- $a Siebert, Reiner $u Institute of Human Genetics, University of Ulm and Ulm University Hospital, Ulm, Germany
- 700 1_
- $a Witt, Olaf $u Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany
- 700 1_
- $a Gerss, Joachim $u Institute of Biostatistics and Clinical Research, University of Münster, Muenster, Germany
- 700 1_
- $a Kerl, Kornelius $u Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany $1 https://orcid.org/0000000256768102
- 700 1_
- $a Frühwald, Michael C $u University Medical Center Augsburg, Paediatric and Adolescent Medicine, Swabian Children's Cancer Center, Augsburg, Germany $1 https://orcid.org/0000000282371854
- 773 0_
- $w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 68, č. 12 (2021), s. e29267
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34347371 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135827 $b ABA008
- 999 __
- $a ok $b bmc $g 1823007 $s 1170869
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 68 $c 12 $d e29267 $e 20210804 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
- LZP __
- $a Pubmed-20220720
